Objective: To review types of lymphoma, risk factors, and evaluate novel immune-mediated therapies, including side effects and management of immune-mediated toxicities.
Data source: Published literature, national statistics, and Web sites.
Conclusion: Novel biologic agents are being developed with the potential to improve outcomes. However, these novel agents pose unique and sometimes serious adverse events.
Implications for nursing practice: The immune-mediated adverse events require a multidisciplinary approach and early identification. It is imperative providers and nurses are educated on the management of the unique toxicities caused by lymphoma treatment.
Keywords: BCL-2 inhibitors; Bruton's tyrosine kinase inhibitors; Checkpoint inhibitors; Hodgkin lymphoma; Immune modulators; Immune-mediated therapy; Monoclonal antibody; Non-Hodgkin lymphoma; PI3 kinase inhibitors.
Copyright © 2019 Elsevier Inc. All rights reserved.